

# Axinn Successfully Represents Alvogen Before FTC

NEWS | LESS THAN 1 MIN READ


November 3, 2015

Axinn successfully represented Alvogen before the Federal Trade Commission in connection with Alvogen's approval to buy the divestiture products in the proposed Mylan/Perrigo transaction. Mylan's bid for Perrigo is valued at \$25 billion, and Alvogen will acquire seven separate pharmaceutical products as a result of the FTC-mandated and approved divestiture. Alvogen was also approved to acquire the divestiture products in Pfizer/Hospira earlier this year. The FTC's Mylan press release can be found [here](#).


The Axinn team based in Washington, DC consisted of partner Michael Keeley, assisted by associate Kenina Lee.

## Related People

---



Michael L. Keeley



Kenina J. Lee

## Related Services

---

Antitrust

To subscribe to our publications, [click here](#).

## Featured Insights

- American Bar Association 2025 Asia-Pacific Conference  
**SPEAKING ENGAGEMENT    ANTITRUST**
- NBA Commercial Law Section 38th Annual Corporate Counsel Conference  
**SPONSORSHIP    ANTITRUST**
- GCR Live: Law Leaders Global 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**
- The 32nd Annual Marketing Partner Forum  
**EVENT**
- SABA North America Corporate Counsel Retreat 2025  
**SPONSORSHIP    ANTITRUST**
- Axinn Antitrust Insight: FTC Announces Revised HSR Thresholds for 2025  
**CLIENT ALERTS    ANTITRUST**
- Four Axinn Thought Leadership Pieces Nominated for the Antitrust Writing Awards  
**AWARDS & RECOGNITIONS    ANTITRUST**

- Merger Remedies Back in Vogue Under Trump

**MEDIA MENTIONS     ANTITRUST**

- Three Takeaways from the Initial Determination at the ITC Regarding Standard Essential Patents in the 1380 Investigation

**AXINN VIEWPOINTS     INTELLECTUAL PROPERTY**

- A POSA's Motivation Is Not Required To Be the Same as the Inventor's in Evaluating Obviousness

**AXINN VIEWPOINTS     INTELLECTUAL PROPERTY**

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved